Navigation Links
Cadence Pharmaceuticals Appoints Stephen L. Newman, M.D., to its Board of Directors
Date:3/14/2013

SAN DIEGO, March 14, 2013 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, announced today the appointment of Stephen L. Newman , M.D., to the company's board of directors.

"We are very pleased to welcome Dr. Newman to our board of directors. His experience in the evolving sector of integrated delivery networks, significant healthcare operations experience, and clinical background will be an invaluable addition to our board as we seek to expand our portfolio of products for use within the hospital setting," stated Cam Garner , Chairman of Cadence.

Dr. Newman served in positions of increasing responsibility with Tenet Healthcare Corporation (NYSE: THC), including as Vice Chairman from January 2012 until his retirement in June 2012. Since joining Tenet in 1999, he also served as Corporate Chief Operating Officer and Executive Vice President of Tenet Healthcare Corporation, Chief Executive Officer of Tenet HealthSystem, California, and as Senior Vice President, Gulf States Region, of Tenet HealthSystem. Prior to joining Tenet, Dr. Newman held executive positions at Columbia/HCA, Inc., and served as Senior Vice President and Chief Medical Officer of Touro Infirmary in New Orleans. Earlier in his career, Dr. Newman was an Associate Professor of Pediatrics and Medicine at Wright State University School of Medicine, and Director of Gastroenterology and Nutrition Support at Children's Medical Center in Dayton, Ohio.  Dr. Newman is currently a member of the Labor, Education and Healthcare Council of the Federal Reserve Bank of Atlanta, and a member of the Board of Directors of Optimer Pharmaceuticals, Inc. and Hansen Medical, Inc.  He holds a bachelor's degree from Rutgers University, an M.B.A. from Tulane University and a medical degree from the University of Tennessee. Dr. Newman completed his internship, residency and fellowship at Emory University School of Medicine, and has also completed the Advanced Management Program at the University of Pennsylvania's Wharton School of Business.

About Cadence Pharmaceuticals, Inc.
Cadence Pharmaceuticals is a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting. The current version of Cadence Pharmaceuticals' corporate overview may be viewed on the Investors page of www.cadencepharm.com under "Events & Presentations" by selecting "Corporate Overview."

CADENCE® and OFIRMEV® are registered trademarks of Cadence Pharmaceuticals, Inc.

 Contact:

William R. LaRue

Kelli FranceSVP & Chief Financial Officer

Media RelationsCadence Pharmaceuticals, Inc.

WCGPhone: 858-436-1400

Phone: 415-946-1076


'/>"/>
SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2012 Financial Results
2. Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss Fourth Quarter And Full Year 2012 Financial Results On March 7, 2013
3. Cadence Pharmaceuticals CEO Ted Schroeder To Present At The Cowen & Company 33rd Annual Health Care Conference In Boston On March 5, 2013
4. Cadence Pharmaceuticals CEO Ted Schroeder To Present At The Leerink Swann Global Healthcare Conference In New York City On February 13, 2013
5. Cadence Pharmaceuticals Estimates Fourth Quarter 2012 Net Product Revenue and Provides Full Year 2013 Revenue Guidance
6. Cadence Pharmaceuticals Announces Termination of Option Agreement to Acquire Incline Therapeutics, Inc.
7. Cadence Pharmaceuticals to Host Analyst and Investor Day
8. Cadence to Open Finished Medical Device Facility
9. Cadence Pharmaceuticals CEO Ted Schroeder To Present At The Piper Jaffray 24th Annual Healthcare Conference In New York City On November 28, 2012
10. Cadence Pharmaceuticals Reports Third Quarter 2012 Financial Results
11. Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss Third Quarter 2012 Financial Results On November 5, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... 19, 2017 Pfizer joins ... Milner Therapeutics Consortium   Major research ... Cambridge   The Milner Therapeutics ... ) as a partner to the Milner Therapeutics Consortium. ... the efficient transfer of materials between industry and academia ...
(Date:1/19/2017)... FRANCISCO , January 19, 2017 The global  pacemaker ... new report by Grand View Research, Inc. The heightening prevalence of cardiac conditions ... the growth of Pacemaker globally. In addition, technological enhancements in these devices are ... ... Grand View Research Logo ...
(Date:1/19/2017)... , Jan. 18, 2017 The Global Therapy ... and access to partnering deals and agreements entered into ... in partnering deals - Top deals by value - ... development, technology type The report provides understanding and ... by the world,s leading healthcare companies. The report ...
Breaking Medicine Technology:
(Date:1/19/2017)... ... January 19, 2017 , ... WhoHaha , a digital media ... American Heart Association (AHA) to produce a three-part video series that uses humor to ... part of the launch of AHA’s Healthy For Good™ movement, which is designed to ...
(Date:1/19/2017)... ... January 19, 2017 , ... Cosmetic Town, an online plastic surgery community, ... to make it easier for their readers to get the information they desire. The ... well as the techniques used on those particular areas. , “We are excited to ...
(Date:1/19/2017)... ... January 19, 2017 , ... Catalent ... for drugs, biologics and consumer health products, today announced that it will be ... leader in innovative excipients and drug delivery solutions to health industries worldwide. The ...
(Date:1/19/2017)... ... January 19, 2017 , ... MB Business ... new $11,250,000 senior credit facility to Sunrise, Florida-based Management Health Systems, LLC, dba ... to facilitate a recapitalization of MedPro led by Harren Equity Partners. Brightwood ...
(Date:1/19/2017)... (PRWEB) , ... January 19, 2017 , ... ... of a doctor who administered fillers that resulted in severe facial disfiguration. After ... was taken on by doctors at UCLA Medical Center, who removed the substances ...
Breaking Medicine News(10 mins):